Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a part of Acorda Therapeutics Inc. Group (”Acorda”) and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.
View Top Employees from Biotie TherapiesWebsite | http://www.biotie.com |
Ticker | NASDAQ:BITI |
Revenue | $4 million |
Funding | $205.8 million |
Employees | 6 (6 on RocketReach) |
Founded | 1998 |
Address | 6 Tykistokatu, Turku, Southwest Finland 20520, FI |
Phone | +358 35822748900 |
Fax | +358 35822748910 |
Technologies |
Google Analytics,
ASP.NET,
Microsoft IIS
+1 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Health Care, Manufacturing, Medical, Pharmaceutical |
Web Rank | 28 Million |
Keywords | Biotie Therapies |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Biotie Therapies employee's phone or email?
The Biotie Therapies annual revenue was $4 million in 2023.
Michael Eison is the Vice President Regulatory Affairs of Biotie Therapies.
6 people are employed at Biotie Therapies.
Biotie Therapies is based in Turku, Southwest Finland.
The NAICS codes for Biotie Therapies are [325, 32, 3254, 32541].
The SIC codes for Biotie Therapies are [283, 28].